Gotenfia's EU Approval Ignites Competition in Autoimmune Drug Market

BAD VILBEL, Germany – February 13, 2026 – The European Commission has granted marketing authorization for Gotenfia, a new biosimilar drug poised to significantly alter the treatment landscape for millions of patients with chronic autoimmune diseases. Developed by China-based Bio-Thera Solutions and set to be commercialized by German pharmaceutical giant STADA, Gotenfia is a biosimilar of the widely used biologic Simponi (golimumab), offering a new, competitive option for conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

The approval marks a critical milestone, signaling intensified competition in a multi-billion dollar market and promising to drive down costs, thereby expanding patient access to life-changing therapies across the European Union.

A New Wave of Competition

Gotenfia’s entry is not just another drug approval; it's a strategic move into a fiercely competitive and growing market. The European autoimmune biologics sector, valued at over $86 billion in 2025, is projected to nearly double by 2032, fueled by an increasing prevalence of immune-mediated inflammatory diseases. Golimumab, the active ingredient in both Simponi and Gotenfia, is a tumor necrosis factor-alpha (TNF-α) inhibitor, a class of drugs that has revolutionized the management of chronic inflammation.

However, STADA and Bio-Thera are not the first to challenge the dominance of Johnson & Johnson's Simponi. In late 2025, Alvotech and Advanz Pharma received approval for Gobivaz, the first golimumab biosimilar in the European Economic Area. Gotenfia’s arrival as the second approved biosimilar is expected to accelerate price erosion and significantly increase pressure on the originator product. This dynamic is a hallmark of the biosimilar market, where multiple competitors are often necessary to unlock the full potential of cost savings for healthcare systems.

"Having received the European marketing authorization, our 11th for a biosimilar in total, we look forward to increasing competition on this well-established anti-TNF therapy," commented STADA's Global Specialty Head, Bryan Kim, in a statement. He emphasized the company's experience with other biosimilars, noting "the considerable impact that access to biological treatments for chronic autoimmune and inflammatory conditions can have on patients' quality of life."

The Economic Ripple Effect

The primary promise of biosimilars like Gotenfia lies in their economic impact. By providing a clinically equivalent alternative at a lower price point, they enable substantial savings for national health systems, which can then be reinvested into other areas of care or used to treat more patients. As of 2022, cumulative savings from biosimilar competition across Europe had already surpassed €30 billion.

The uptake and pricing of biosimilars vary significantly across the continent, dictated by national reimbursement policies:

• United Kingdom: The NHS has aggressively pursued biosimilar adoption through centralized negotiations and switching policies, leading to price erosion of up to 60% for some biologics and saving the system hundreds of millions of pounds annually.
• Germany: The market relies on a reference pricing system and negotiations at the hospital level. While automatic substitution is not standard, high physician acceptance and immediate reimbursement have fostered strong biosimilar uptake.
• France: The country incentivizes biosimilar use through a combination of regulated price cuts, often around 40% below the originator, and gain-sharing models that allow hospitals and prescribers to benefit from the savings they generate.

Gotenfia's launch will navigate this complex landscape, with STADA's extensive commercial experience in Europe being a key asset in securing market share and driving adoption.

A Global Partnership for Biosimilar Leadership

The approval of Gotenfia is a testament to the powerful synergy between Bio-Thera Solutions and STADA. Their partnership, initiated in May 2024, leverages the distinct strengths of each company: Bio-Thera's expertise in complex biologic development and manufacturing, and STADA's formidable commercialization infrastructure across Europe.

Under the agreement, Bio-Thera is responsible for development, manufacturing, and supply, while STADA holds exclusive rights to commercialize the product in the EU, the UK, Switzerland, and other key markets. This model allows the Chinese biopharmaceutical firm to access the lucrative European market without building a commercial presence from the ground up.

"Bringing this convenient, once-monthly treatment option to rheumatologists, gastroenterologists and the patients they serve marks a major milestone in Bio-Thera's commitment to being one of the premier biosimilar developers and manufacturers in the world," stated Shengfeng Li, CEO of Bio-Thera Solutions.

This collaboration is not a one-off venture. In 2025, the partners extended their alliance to include a biosimilar for tocilizumab (Actemra/RoActemra), another blockbuster autoimmune drug. This deepening relationship underscores a shared long-term strategy to become leaders in the European biosimilar space, particularly within the high-value immunology sector. For STADA, Gotenfia represents its 11th approved biosimilar in Europe, cementing its status as a top-tier player in the field.

What This Means for Patients and Physicians

Beyond market dynamics and corporate strategy, the central impact of Gotenfia's approval is on patients and their doctors. For individuals living with debilitating chronic conditions, the availability of more treatment options is crucial. The European Medicines Agency (EMA) authorized Gotenfia based on a "totality of evidence" approach, which includes a comprehensive package of analytical, non-clinical, and clinical data demonstrating its high similarity to the reference product, Simponi, in terms of safety, quality, and efficacy.

The EMA considers approved biosimilars to be scientifically interchangeable with their reference products, giving physicians confidence to prescribe them. Gotenfia will be available in 50mg and 100mg pre-filled syringes equipped with passive needle safety guards, a practical feature designed to enhance convenience and safety for patients who self-administer their treatment.

By fostering competition and lowering prices, the introduction of Gotenfia is expected to broaden access to golimumab for patients who may have previously faced barriers due to high costs. This can lead to earlier intervention with advanced biologic therapies, potentially improving long-term health outcomes and quality of life. The increased affordability allows healthcare systems to treat more patients within the same budget, ensuring that the benefits of modern medicine reach a wider population.